Review Highlights Myeloid-Derived Suppressor Cells as Key Therapeutic Target in Glioblastoma
Background
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that are significantly expanded in malignant diseases, including aggressive brain cancers like glioblastoma (GBM). These cells are functionally immunosuppressive, posing a major challenge to effective anti-tumor immunity. The highly immunosuppressive nature of high-grade gliomas like GBM often renders conventional and emerging immunotherapies less effective. MDSCs contribute to this by infiltrating the tumor microenvironment and suppressing anti-tumor immune responses, making them a critical barrier to successful treatment and a compelling target for novel therapeutic interventions.
Study Design
This comprehensive review synthesized extensive preclinical and translational research on Myeloid-Derived Suppressor Cells (MDSCs) in glioblastoma (GBM). The authors provided a detailed summary of MDSC function, migration, and expansion, integrating insights from clinical observations and large-scale multi-omics studies. They meticulously covered multiple chemokines, cytokines, and growth factors relevant to MDSC biology, along with their associated receptors, which influence MDSC migration, survival, and expansion. The review also discussed various therapeutic approaches designed to directly target MDSCs as a strategy to improve immune responses against malignant brain tumors, noting observed changes in MDSCs within the tumor microenvironment following immunotherapy.
Results
The review firmly established Myeloid-Derived Suppressor Cells (MDSCs) as central players in glioblastoma (GBM) immunosuppression, highlighting their critical role in facilitating tumor progression and hindering effective anti-tumor immunity. MDSCs express a diverse array of chemokine and cytokine receptors that are instrumental in their entry, infiltration, expansion, and the subsequent suppression of anti-tumor immune responses within the tumor microenvironment. The synthesis of clinical observations and multi-omics data strongly positions MDSCs at the nexus of GBM's profound immunosuppressive phenotype. This comprehensive analysis underscores their significant influence on immune cell function and overall immune responses against neoplastic cells, making them a pivotal target for therapeutic intervention.
Translational investigations targeting MDSCs, either directly or indirectly through immune remodeling, have yielded promising effects that are currently under clinical trial investigation.
Key Findings
- MDSCs are expanded in glioblastoma (GBM) and are central to its profound immunosuppressive phenotype.
- MDSCs express multiple chemokine and cytokine receptors, facilitating their infiltration and expansion in the tumor microenvironment.
- Translational investigations targeting MDSCs directly or indirectly show promising therapeutic effects under clinical investigation.
- Multi-omics studies position MDSCs at the nexus of GBM immunosuppression, influencing anti-tumor immunity.
Why It Matters
Targeting Myeloid-Derived Suppressor Cells (MDSCs) represents a clinically relevant and promising strategy to enhance immune responses against glioblastoma (GBM). This review provides a vital resource for the neuro-oncology community, guiding scientists and clinicians toward developing more effective immunotherapies by overcoming MDSC-mediated immunosuppression. By detailing the specific chemokines, cytokines, and growth factors that govern MDSC behavior, it informs the rational design of novel agents capable of disrupting MDSC migration, survival, and expansion. Ultimately, a deeper understanding and successful modulation of MDSCs could transform current treatment paradigms for this aggressive brain cancer, potentially improving patient outcomes by dismantling a key immunosuppressive barrier.
glioblastoma
mdsc
immunosuppression
tumor-microenvironment
neuro-oncology
review